Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug

(Business Wire)

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

In what may be a relief for some investors, its big, highly anticipated KRAS drug AMG 510 is already fully enrolled, and the company doesn’t see any “significant delays” for results here. (Though that line doesn’t rule out any smaller delays.)

The biopharma is currently undertaking a “potentially pivotal” phase 2 for the KRAS inhibitor in certain lung cancer patients and has high hopes this med (which was one of the most talked about targets of 2019) will continue on its clinical path relatively uninterrupted.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

The same goes for the tezepelumab phase 3 asthma study, which is partnered with AstraZeneca, and the omecamtiv mecarbil phase 3 heart failure study, which is being worked on alongside Cytokinetics.

These, too, are fully enrolled, and thus, Amgen said, “we do not anticipate significant delays in obtaining results.”

RELATED: Amgen's KRAS drug continues to deliver but faces 'curse' of high expectations

But delays could still hit the biopharma. It said an “increasing number of clinical trial sites are restricting site visits and imposing restrictions” on new trials as well as patient visits to limit COVID-19 exposure.

Given this, it said it is making decisions “study-by-study” and “country-by-country” but has already temporarily paused enrollment/screening in clinical trials “where there is uncertainty around the ability of sites to ensure subject safety or data integrity at the present time.”

Amgen will allow patients to join studies where there is the potential for “significant benefit in a serious or life-threatening condition” and where site resources allow new patients to be safely enrolled and closely monitored.

It added: “We are actively implementing remote and local procedures per recent FDA guidance and working with investigators for appropriate care of these patients in a safe manner consistent with agency guidelines.”

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.